ReviewAIDS research and therapy2025
At a crossroads: confronting setbacks and advancing the 95-95-95 HIV targets in sub-Saharan Africa.
Review in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Implementation Lessons and Policy Implications of Same-Day Antiretroviral Therapy Initiation: Insights from the ART Same-Day Counselling and Initiation (ASCI) SOP in South Africa.International journal of environmental research and public health · 2026Trial
- Predicting the spatiotemporal evolution of HIV/AIDS in Africa: A retrospective analysis of epidemiological trends.Infectious Disease Modelling · 2026Article
- Evaluation of HIV/AIDS Knowledge and Stigma among Algerian University Students.Journal of community health · 2026Article
- U.S. Funding Cuts and Health System Challenges in Community-Based HIV Programmes in Rural KwaZulu-Natal, South Africa: A Qualitative Study.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sub-Saharan Africa (SSA) remains at the epicentre of the global HIV epidemic and faces a decisive moment in its journey toward achieving the UNAIDS 95-95-95 targets. This review aims to provide a comprehensive overview of the progress toward these targets in SSA, identifying key challenges, barriers to viral load suppression, and potential strategies to improve treatment adherence and health outcomes. These goals-ensuring that 95% of people living with HIV know their status, 95% of those diagnosed are receiving treatment, and 95% of those receiving treatment achieve VLS-represent a bold vision to end HIV as a public health threat by 2030. However, across the region, progress is threatened by persistent structural barriers, entrenched stigma, health system weaknesses, and recent global funding disruptions, including the 2025 freeze on U.S. foreign aid. This review explores the multifaceted obstacles that continue to hinder the HIV response in SSA, from testing gaps to challenges in care retention and VLS, particularly among vulnerable populations. It further examines the potential consequences of funding cuts for health system resilience and epidemic control. Emphasising the need for equity-driven, locally adapted, and innovative strategies-such as community-based service delivery, digital health tools, long-acting therapies, and integrated care models-this article argues for renewed political commitment, sustainable financing, and stronger local and global partnerships. When setbacks loom large, this piece calls for urgent, coordinated action to protect progress, address persistent inequities, and secure a future where epidemic control is truly within reach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.